Replies to post #1288 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

Correct mantoo123. This is what I wrote back in June:

From ASCO, it is good to see that the continuous exposure (CE) group had lower KPS and higher rate of 2nd recurrence BUT achieved longer median OS.

Notes from ASCO:
The overall response rate (ORR) for the continuous exposure group was 29% (7/24), and 2 patients experienced complete responses. (CRs) One of the CRs occurred using single-agent VB-111, and the patient remains in remission as of 39 months. Notably, patients in the continuous exposure group had an overall lower Karnofsky performance status (KPS), a less successful initial resection, and had a higher rate of second recurrence than the limited exposure group at baseline, increasing our confidence in the prior survival results with VB-111.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=132017781